184 related articles for article (PubMed ID: 19804461)
21. Crystals and tablets in the Spanish ecstasy market 2000-2014: Are they the same or different in terms of purity and adulteration?
Vidal Giné C; Ventura Vilamala M; Fornís Espinosa I; Gil Lladanosa C; Calzada Álvarez N; Fitó Fruitós A; Rodríguez Rodríguez J; Domíngo Salvany A; de la Torre Fornell R
Forensic Sci Int; 2016 Jun; 263():164-168. PubMed ID: 27129144
[TBL] [Abstract][Full Text] [Related]
22. Solid-phase extraction for profiling of ecstasy tablets.
Rashed AM; Anderson RA; King LA
J Forensic Sci; 2000 Mar; 45(2):413-7. PubMed ID: 10782963
[TBL] [Abstract][Full Text] [Related]
23. Characteristics and trends of 3,4-methylenedioxymethamphetamine (MDMA) tablets found in Taiwan from 2002 to February 2005.
Teng SF; Wu SC; Liu C; Li JH; Chien CS
Forensic Sci Int; 2006 Sep; 161(2-3):202-8. PubMed ID: 16842946
[TBL] [Abstract][Full Text] [Related]
24. Pill content, dose and resulting plasma concentrations of 3,4-methylendioxymethamphetamine (MDMA) in recreational 'ecstasy' users.
Morefield KM; Keane M; Felgate P; White JM; Irvine RJ
Addiction; 2011 Jul; 106(7):1293-300. PubMed ID: 21320226
[TBL] [Abstract][Full Text] [Related]
25. Monitoring ecstasy content in France: results from the National Surveillance System 1999-2004.
Giraudon I; Bello PY
Subst Use Misuse; 2007; 42(10):1567-78. PubMed ID: 17918027
[TBL] [Abstract][Full Text] [Related]
26. Quantitative determination of 3,4-methylenedioxymethamphetamine by thin-layer chromatography in ecstasy illicit pills in Tehran.
Shetab Boushehri SV; Tamimi M; Kebriaeezadeh A
Toxicol Mech Methods; 2009 Nov; 19(9):565-9. PubMed ID: 20047512
[TBL] [Abstract][Full Text] [Related]
27. Variability in content and dissolution profiles of MDMA tablets collected in the UK between 2001 and 2018 - A potential risk to users?
Couchman L; Frinculescu A; Sobreira C; Shine T; Ramsey J; Hecht M; Kipper K; Holt D; Johnston A
Drug Test Anal; 2019 Aug; 11(8):1172-1182. PubMed ID: 31009168
[TBL] [Abstract][Full Text] [Related]
28. A turn-on fluorogenic probe for detection of MDMA from ecstasy tablets.
Moreno D; Díaz de Greñu B; García B; Ibeas S; Torroba T
Chem Commun (Camb); 2012 Mar; 48(24):2994-6. PubMed ID: 22314849
[TBL] [Abstract][Full Text] [Related]
29. Supported liquid-liquid extraction of the active ingredient (3,4-methylenedioxymethylamphetamine) from ecstasy tablets for isotopic analysis.
de Korompay A; Hill JC; Carter JF; NicDaeid N; Sleeman R
J Chromatogr A; 2008 Jan; 1178(1-2):1-8. PubMed ID: 18070626
[TBL] [Abstract][Full Text] [Related]
30. Increased intensity of Ecstasy and polydrug usage in the more experienced recreational Ecstasy/MDMA users: a WWW study.
Scholey AB; Parrott AC; Buchanan T; Heffernan TM; Ling J; Rodgers J
Addict Behav; 2004 Jun; 29(4):743-52. PubMed ID: 15135556
[TBL] [Abstract][Full Text] [Related]
31. [Designer drugs in Jutland].
Simonsen KW; Kaa E
Ugeskr Laeger; 2001 Apr; 163(16):2248-52. PubMed ID: 11344661
[TBL] [Abstract][Full Text] [Related]
32. Multiple drug ingestion by ecstasy abusers in the United States.
Black DL; Cawthon B; Robert T; Moser F; Caplan YH; Cone EJ
J Anal Toxicol; 2009 Apr; 33(3):143-7. PubMed ID: 19371462
[TBL] [Abstract][Full Text] [Related]
33. Analysis of illicit ecstasy tablets: implications for clinical management in the accident and emergency department.
Sherlock K; Wolff K; Hay AW; Conner M
J Accid Emerg Med; 1999 May; 16(3):194-7. PubMed ID: 10353046
[TBL] [Abstract][Full Text] [Related]
34. Hair concentrations and self-reported abuse history of 20 amphetamine and ecstasy users.
Rothe M; Pragst F; Spiegel K; Harrach T; Fischer K; Kunkel J
Forensic Sci Int; 1997 Sep; 89(1-2):111-28. PubMed ID: 9306670
[TBL] [Abstract][Full Text] [Related]
35. Caffeine promotes hyperthermia and serotonergic loss following co-administration of the substituted amphetamines, MDMA ("Ecstasy") and MDA ("Love").
McNamara R; Kerans A; O'Neill B; Harkin A
Neuropharmacology; 2006 Jan; 50(1):69-80. PubMed ID: 16188283
[TBL] [Abstract][Full Text] [Related]
36. Qualitative review of serotonin syndrome, ecstasy (MDMA) and the use of other serotonergic substances: hierarchy of risk.
Silins E; Copeland J; Dillon P
Aust N Z J Psychiatry; 2007 Aug; 41(8):649-55. PubMed ID: 17620161
[TBL] [Abstract][Full Text] [Related]
37. MDMA in humans: factors which affect the neuropsychobiological profiles of recreational ecstasy users, the integrative role of bioenergetic stress.
Parrott AC
J Psychopharmacol; 2006 Mar; 20(2):147-63. PubMed ID: 16510474
[TBL] [Abstract][Full Text] [Related]
38. Neural mechanisms of working memory in ecstasy (MDMA) users who continue or discontinue ecstasy and amphetamine use: evidence from an 18-month longitudinal functional magnetic resonance imaging study.
Daumann J; Fischermann T; Heekeren K; Thron A; Gouzoulis-Mayfrank E
Biol Psychiatry; 2004 Sep; 56(5):349-55. PubMed ID: 15336517
[TBL] [Abstract][Full Text] [Related]
39. 4-Fluoroamphetamine in the Netherlands: more than a one-night stand.
Linsen F; Koning RP; van Laar M; Niesink RJ; Koeter MW; Brunt TM
Addiction; 2015 Jul; 110(7):1138-43. PubMed ID: 25808511
[TBL] [Abstract][Full Text] [Related]
40. The Drug Information and Monitoring System (DIMS) in the Netherlands: implementation, results, and international comparison.
Brunt TM; Niesink RJ
Drug Test Anal; 2011 Sep; 3(9):621-34. PubMed ID: 21898860
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
